Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

45.820
+1.4003.15%
Volume:1.26M
Turnover:57.43M
Market Cap:304.11B
PE:33.14
High:46.160
Open:45.200
Low:44.960
Close:44.420
52wk High:94.869
52wk Low:43.020
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:3.36
T/O Rate:0.49%
Dividend:0.23
Dividend Rate:0.51%
EPS(LYR):1.382
ROE:12.46%
ROA:7.02%
PB:4.03
PE(LYR):33.14
PS:8.29

Loading ...

Citigroup's Short Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Decreases to 1.39% on Aug 3 from 2.36% - HKEX

THOMSON REUTERS
·
Aug 07

August 7th A-H Share Premium Data Summary

Stock News
·
Aug 07

HENGRUI PHARMA Shares Surge Over 4% in Late Trading as China's First Anti-HER2 Product for Colorectal Cancer Gains Market Approval

Stock News
·
Aug 07

Movement Alert|HENGRUI PHARMA Rises 3.1% in Regular Trading, Two Innovative Drugs Approved for New Indications

Market Focus
·
Aug 07

Hengrui Pharma Unit Gets Marketing Nod for Colorectal Cancer Drug in China

MT Newswires Live
·
Aug 06

Hengrui Pharma Secures China’s First Anti-HER2 Approval for Colorectal Cancer with Trastuzumab Rezetecan

Bulletin Express
·
Aug 06

Jiangsu Hengrui Pharmaceuticals - Nmpa Approved Additional (Fifth) Indication for Ivarmacitinib Sulfate Tablets (Shr0302 Tablets)

THOMSON REUTERS
·
Aug 06

Jiangsu Hengrui Pharmaceuticals - Nmpa Approves Third Indication for Trastuzumab Rezetecan for Injection for Marketing in China

THOMSON REUTERS
·
Aug 06

JAK1 Inhibitor Aisuda Secures Fifth Indication Approval for Active Non-Radiographic Axial Spondyloarthritis

Deep News
·
Aug 06

Jiangsu Hengrui Pharmaceuticals Secures Approval for Third Indication of Its Anti-HER2 Injection

Stock News
·
Aug 06

Citigroup’s Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 5.06% on July 31 from 4.46% - HKEX Filing

THOMSON REUTERS
·
Aug 06

HENGRUI PHARMA's Zhang Lianshan: Global Strategy at a Turning Point, Innovative Drug Firms Must Ultimately Go Global Independently

Deep News
·
Aug 06

Movement Alert|HENGRUI PHARMA Falls 3.09% in Regular Trading, Trading at HK$56.35

Market Focus
·
Aug 06

Cross-Market Valuation Disparities: Top A-H Share Premium Rankings as of August 5th

Stock News
·
Aug 05

Hengrui Pharmaceuticals Gets China Nod for Lung Cancer Combo Trials

MT Newswires Live
·
Aug 05

Hengrui Pharma Completes 13.75 Million Share Buyback as of July 31

Stock News
·
Aug 04

HENGRUI PHARMA's Subsidiary Secures Approval for Clinical Trial Initiation

Stock News
·
Aug 04

Hengrui Pharma Maintains Stable H-Share Base; Repurchases 0.28 Million A-Shares in July

Bulletin Express
·
Aug 04

Dual-Listed Stock Premium Snapshot: August 3 Market Close

Stock News
·
Aug 03

Metis TechBio Jumps on Jiangsu Hengrui-tie up on AI Formulation Platform

Reuters
·
Aug 03